Wed 6/3/2020 06:59 ET
S&P 5003080.8225.260.82%BANKS345.741.940.56%OIL35.341.634.61%BITCOIN9596.6972.930.76%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Wall Street Pit (Caladrius Biosciences, Inc - CLBS)    Stock Due Diligence for All

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CLBS
From: SunTzu772 (Rep: 1326) reply to stormcatDate: 05/23/2020 14:38
Forum: Wall Street Pit - Msg #2848943 - List CLBS msgs Thread #674159392 (Rec: 3)
Re: next week we be over $3.00 folks...2.15 a/h big buyer of (October 16) $5 Calls yesterday.
I hold June $3 Calls and am building a significant core in the common..this is one of the most transparent and efficient spending small bios (Cash = Market Cap, enough to last through Q3 2021) and imho according to my DD has the making and ingredients of being an absolute monster..the real trend with clinical stage biotechs is almost always the opposite of the knee-jerk buy or sell the news reaction.

Brookline starts Caladrius Biosciences at buy; PT $7

"Caladrius is developing cellular therapies for ischemic diseases. Its CD34 technology platform uses a patient’s own CD34+ cells for self-repair and restoration.

“Unlike conventional cell therapies, the CD34+ cell platform eliminates the need for genetic modifications, cell expansion, and offers a faster, compatible, localized, cost-effective potential cell-therapy,” writes analyst Kumaraguru Raja.

Caladrius has three candidate drugs – CLBS12, CLBS14 and CLBS16 – in clinical studies and recently filed an IND for a new drug candidate, CLBS119, for treatment of COVID-19 patients with severe respiratory distress related to infection and ventilation.

Mr. Raja said CLBS12 is being developed for the treatment of critical limb ischemia, and is a recipient of Japanese breakthrough designation for early conditional approval in Japan. “The anticipated completion for this study is the end of 2020 or early 2021, and potential commercialization of CLBS12 in late 2021/early 2022,” he added.

“We believe that the company presents a favorable risk-reward proposition and see potential for partnerships, or collaborations with pipeline advance and clinical success,” Mr. Raja said."


H.C. Wainwright Sticks to Their Buy Rating for Caladrius Biosciences (CLBS)
Caladrius Biosciences (NASDAQ: CLBS)In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Caladrius Biosciences with a price target of $18.50.

------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------

Reply to stormcat - Msg #2848857 - 05/22/2020 15:56

next week we be over $3.00 folks... they will find this monster over the weekend
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SunTzu772: Reward | Watch | IgnoreCLBS: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add CLBS | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999-, Inc.